CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond.

Jiankang HuYong Xu

Published in: Journal of medicinal chemistry (2024)

Transcriptional coactivators CBP/p300 have emerged as potential targets for cancer therapeutics. This Viewpoint discusses recent results that demonstrate an exceptionally potent and orally efficacious CBP/p300 degrader for the treatment of prostate cancer. This degrader stands out as a promising new candidate for cancer therapy and deserves further research.

Keyphrases

prostate cancer
cancer therapy
small molecule
squamous cell carcinoma
papillary thyroid
climate change
risk assessment
replacement therapy
childhood cancer